Crovalimab - Chugai Pharmaceutical/Roche
Alternative Names: Anti-C5 recycling antibody - Chugai Pharmaceutical/Roche; CH-7092230; Crovalimab-akkz; Piasky; RG 6107; RO 7092230; RO-7112689; RO-711269; RO7112689/F01; SKY-59Latest Information Update: 28 Feb 2025
At a glance
- Originator Chugai Pharmaceutical
- Developer Chugai Pharmaceutical; Roche
- Class Antianaemics; Monoclonal antibodies; Urologics
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Paroxysmal nocturnal haemoglobinuria
- Phase III Atypical Haemolytic Uraemic Syndrome
- Phase II Sickle cell anaemia
- Discontinued Lupus nephritis
Most Recent Events
- 07 Dec 2024 Adverse events and efficacy data from the phase-III COMMODORE-1 trial in Paroxysmal nocturnal hemoglobinuria presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024) ,
- 07 Dec 2024 Efficacy and adverse events data from the phase III COMMODORE 2 trial in paroxysmal nocturnal hemoglobinuria presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
- 07 Dec 2024 Adverse events and efficacy data from a phase III COMMODORE 1 trial in Paroxysmal nocturnal haemoglobinuria presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)